Drug intelligence / Profile preview

ART24

Development stage: Phase 1
Lead developer: Adiso Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

ART24, also known as ADS024, is an orally administered, single-strain live biotherapeutic product (SS-LBP). [2] It consists of a pure, clonal strain of *Bacillus velezensis*. [3, 4] The drug was discovered through a collaboration between Artugen Therapeutics and APC Microbiome Ireland and is being developed by Adiso Therapeutics, which acquired Artugen. [4, 5] ART24 is intended for the prevention of recurrent *Clostridioides difficile* infection (CDI). [4, 6] Its mechanisms of action include directly killing *C. difficile* and producing proteases that degrade its toxins, TcdA and TcdB. [3, 4, 7] It has completed a Phase 1b clinical trial in patients recently cured of CDI. [2, 7]

Targets

TcdB (Clostridioides difficile large clostridial toxin family)TcdA (Clostridioides difficile toxin A)

Beyond the preview

Go deeper on ART24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART24.

Explore the full profile